Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma

Clinical Cancer Research

Volumn 12, Issue 9, 2006, Pages 2689-2697

  Komori, Hiroyuki ^a   Nakatsura, Tetsuya ^a,d   Senju, Satoru ^a   Yoshitake, Yoshihiro ^a   Motomura, Yutaka ^a   Ikuta, Yoshiaki ^a   Fukuma, Daiki ^a   Yokomine, Kazunori ^a   Harao, Michiko ^a   Beppu, Toru ^a   Matsui, Masanori ^b   Torigoe, Toshihiko ^c   Sato, Noriyuki ^c   Baba, Hideo ^a   Nishimura, Yasuharu ^a,e  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYPICAN; GPC3 [102-110]; GPC3 [144-152]; GPC3 [155-163]; GPC3 [169-177]; GPC3 [254-268]; GPC3 [281-289]; GPC3 [298-306]; GPC3 [326-334]; GPC3 [44-52]; GPC3 [522-560]; HLA A2 ANTIGEN; HLA A24 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EPITOPES; GLYPICANS; HEPARAN SULFATE PROTEOGLYCANS; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MICE; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33646721733     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2267     Document Type: Article

References (32)

1. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353:1253-7.
2. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000;232:10-24.
3. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
4. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin 2005;55:10-30.
5. 2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-23.
6. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
7. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25.
8. Nakatsura T, Kageshita T, Ito S, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004;10:6612-21.
9. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-64.
10. Nakatsura T, Komori H, Kubo T, et al. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004;10:8630-40.
11. Browning M, Krausa P. Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol Today 1996;17:165-70.
12. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from β2 microglobulin (p2m) HLA-A2.1 monochain transgenic H-2Db β2m double knockout mice. J Exp Med 1997;185:2043-51.
13. Firat H, Garcia-Pons F, Tourdot S, et al. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol 1999;29:3112-21.
14. Henderson RA, Michel H, Sakaguchi K, et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992;255:1264-6.
15. Karaki S, Kariyone A, Kato N, Kano K, Iwakura Y, Takiguchi M. HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-specific antibodies. Immunogenetics 1993;37:139-42.
16. Wadee AA, Paterson A, Coplan KA, Reddy SG. HLA expression in hepatocellular carcinoma cell lines. Clin Exp Immunol 1994;97:328-33.
17. Matsui M, Machida S, Itani-Yohda T, Akatsuka T. Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-γ. J Gastroenterol Hepatol 2002;17:897-907.
18. Bourgault Villada I, Moyal Barracco M, Ziol M, et al. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res 2004;64:8761-6.
19. Yoshitake Y, Nakatsura T, Monji M, et al. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res 2004;10:6437-48.
20. Monji M, Nakatsura T, Senju S, et al. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res 2004;10:6047-57.
21. Makita M, Hiraki A, Azuma T, et al. Antilung cancer effect of WT1-specific cytotoxicT lymphocytes. Clin Cancer Res 2002;8:2626-31.
22. Gomi S, Nakao M, Niiya F, et al. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J Immunol 1999;163:4994-5004.
23. Kai M, Nakatsura T, Egami H, Senju S, Nishimura Y, Ogawa M. Heat shock protein 105 is overexpressed in a variety of human tumors. Oncol Rep 2003;10:1777-82.
24. Matsuyoshi H, Senju S, Hirata S, Yoshitake Y, Uemura Y, Nishimura Y. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination. J Immunol 2004;172:776-86.
25. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621-67.
26. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297-306.
27. Bredenbeck A, Losch FO, Sharav T, et al. Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy. J Immunol 2005;174:6716-24.
28. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res 1997;16:313-39.
29. Tsuboi A, Oka Y, Udaka K, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002;51:614-20.
30. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005;65:6245-54.
31. Senju S, Hirata S, Matsuvoshi H, et al. Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells. Blood 2003;101:3501-8.
32. Motomura Y, Senju S, Nakatsura T, et al. Embryonic stem cell-derived dendritic cells expressing Glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-10. Cancer Res 2006;66:2414-22.